Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envelope glycoprotein D (gD2) is an essential structural component of the Herpes simplex virus type 2 (HSV-2) envelope. It plays a critical role in viral entry and cell-to-cell spread by binding to specific host cell receptors, including nectin-1, nectin-2, and herpesvirus entry mediator (HVEM). This binding event triggers conformational changes in other viral glycoproteins (gB and the gH/gL complex), leading to the fusion of the viral envelope with the host cell membrane. Because of its indispensable role in infectivity and its high immunogenicity, gD2 has been a primary target for the development of prophylactic and therapeutic vaccines, as well as neutralizing monoclonal antibodies. Historically, subunit vaccines targeting gD2 (such as GSK's Simplirix/Herpevac) induced robust neutralizing antibodies but failed to protect against HSV-2 infection in clinical trials, likely due to rapid antibody decline and shielding of gD2 by other viral glycoproteins like gC and gE. Modern therapeutic approaches include monoclonal antibodies like UB-621, which block the gD-receptor interface to prevent viral entry, and next-generation mRNA vaccines (such as BioNTech's BNT163 and Moderna's mRNA-1608) that combine gD2 with other viral antigens to overcome immune evasion and elicit broader, more durable immune responses.
Neutralization of viral entry and cell-to-cell spread by blocking the interaction of glycoprotein D with host cell receptors (such as nectin-1, nectin-2, and herpesvirus entry mediator [HVEM]), thereby preventing viral fusion and infection.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope glycoprotein D (gD2).